Characterization of Human Pancreatic Orthotopic Tumor Xenografts Suitable for Drug Screening

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2011 Jun 18

PMID 21681527

Citations 16

Authors

Sandra Perez-Torras

Anna Vidal-Pla

Rosa Miquel

Vanessa Almendro

Laureano Fernandez-Cruz

Salvador Navarro

Joan Maurel

Neus Carbo

Pere Gascon

Adela Mazo

Affiliations

Soon will be listed here.

Abstract

Background: Efforts to identify novel therapeutic options for human pancreatic ductal adenocarcinoma (PDAC) have failed to result in a clear improvement in patient survival to date. Pancreatic cancer requires efficient therapies that must be designed and assayed in preclinical models with improved predictor ability. Among the available preclinical models, the orthotopic approach fits with this expectation, but its use is still occasional.

Methods: An in vivo platform of 11 orthotopic tumor xenografts has been generated by direct implantation of fresh surgical material. In addition, a frozen tumorgraft bank has been created, ensuring future model recovery and tumor tissue availability.

Results: Tissue microarray studies allow showing a high degree of original histology preservation and maintenance of protein expression patterns through passages. The models display stable growth kinetics and characteristic metastatic behavior. Moreover, the molecular diversity may facilitate the identification of tumor subtypes and comparison of drug responses that complement or confirm information obtained with other preclinical models.

Conclusions: This panel represents a useful preclinical tool for testing new agents and treatment protocols and for further exploration of the biological basis of drug responses.

Citing Articles

The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids.

Low R, Lim W, Nguyen P, Lee B, Christie M, Burgess A Cancers (Basel). 2021; 13(19).

PMID: 34638463 PMC: 8508245. DOI: 10.3390/cancers13194979.

Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.

Pham N, Radulovich N, Ibrahimov E, Martins-Filho S, Li Q, Pintilie M Sci Rep. 2021; 11(1):10619.

PMID: 34011980 PMC: 8134568. DOI: 10.1038/s41598-021-90049-1.

Impact of immediate cryopreservation on the establishment of patient derived xenografts from head and neck cancer patients.

Abel L, Durmaz A, Hu R, Longhurst C, Baschnagel A, Wheeler D J Transl Med. 2021; 19(1):180.

PMID: 33910584 PMC: 8082827. DOI: 10.1186/s12967-021-02850-1.

Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma.

He M, Henderson M, Muth S, Murphy A, Zheng L Ann Pancreat Cancer. 2020; 3.

PMID: 32832900 PMC: 7440242. DOI: 10.21037/apc.2020.03.03.

Patient Derived Models to Study Head and Neck Cancer Radiation Response.

Cosper P, Abel L, Lee Y, Paz C, Kaushik S, Nickel K Cancers (Basel). 2020; 12(2).

PMID: 32059418 PMC: 7072508. DOI: 10.3390/cancers12020419.

References

Kumar S, Weaver V . Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009; 28(1-2):113-27. PMC: 2658728. DOI: 10.1007/s10555-008-9173-4. View

Talmadge J, Singh R, Fidler I, Raz A . Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol. 2007; 170(3):793-804. PMC: 1864878. DOI: 10.2353/ajpath.2007.060929. View

Singh A, Chaturvedi P, Batra S . Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res. 2007; 67(2):433-6. DOI: 10.1158/0008-5472.CAN-06-3114. View

Garber K . From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst. 2009; 101(1):6-8. DOI: 10.1093/jnci/djn481. View

Bergmann U, Funatomi H, Yokoyama M, Beger H, Korc M . Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995; 55(10):2007-11. View

Williams A, Smartt H, H-Zadeh A, MacFarlane M, Paraskeva C, Collard T . Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ. 2006; 14(1):137-45. DOI: 10.1038/sj.cdd.4401919. View

Fu X, Guadagni F, Hoffman R . A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A. 1992; 89(12):5645-9. PMC: 49349. DOI: 10.1073/pnas.89.12.5645. View

Bibby M . Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer. 2004; 40(6):852-7. DOI: 10.1016/j.ejca.2003.11.021. View

Karna E, Surazynski A, Orlowski K, Laszkiewicz J, Puchalski Z, Nawrat P . Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. Int J Exp Pathol. 2003; 83(5):239-45. PMC: 2517686. DOI: 10.1046/j.1365-2613.2002.00237.x. View

10.

Chu G, Kimmelman A, Hezel A, DePinho R . Stromal biology of pancreatic cancer. J Cell Biochem. 2007; 101(4):887-907. DOI: 10.1002/jcb.21209. View

11.

Kim M, Evans D, Wang H, Abbruzzese J, Fleming J, Gallick G . Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009; 4(11):1670-80. PMC: 4203372. DOI: 10.1038/nprot.2009.171. View

12.

Kung A . Practices and pitfalls of mouse cancer models in drug discovery. Adv Cancer Res. 2006; 96:191-212. DOI: 10.1016/S0065-230X(06)96007-2. View

13.

Ueda S, Hatsuse K, Tsuda H, Ogata S, Kawarabayashi N, Takigawa T . Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod Pathol. 2006; 19(6):788-96. DOI: 10.1038/modpathol.3800582. View

14.

Horndler C, Gallego R, Garcia-Albeniz X, Alonso-Espinaco V, Alonso V, Escudero P . Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. Cancer Biol Ther. 2010; 11(2):177-83. DOI: 10.4161/cbt.11.2.13839. View

15.

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

16.

Berlin J, Catalano P, Thomas J, Kugler J, Haller D, Benson 3rd A . Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20(15):3270-5. DOI: 10.1200/JCO.2002.11.149. View

17.

Ozawa F, Friess H, Kleeff J, Xu Z, Zimmermann A, Sheikh M . Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 2001; 163(1):71-81. DOI: 10.1016/s0304-3835(00)00660-1. View

18.

Rubio-Viqueira B, Hidalgo M . Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther. 2008; 85(2):217-21. DOI: 10.1038/clpt.2008.200. View

19.

Kindler H . Pancreatic cancer: an update. Curr Oncol Rep. 2007; 9(3):170-6. DOI: 10.1007/s11912-007-0018-z. View

20.

Guix M, de Matos Granja N, Meszoely I, Adkins T, Wieman B, Frierson K . Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol. 2008; 26(6):897-906. DOI: 10.1200/JCO.2007.13.5939. View